Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
about
Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormoneBrain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Biomarkers in Multiple Sclerosis: An Up-to-Date OverviewClinical, MRI, and CSF markers of disability progression in multiple sclerosis.Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysisA panel of neuron-enriched proteins as markers for traumatic brain injury in humans.Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation.Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the futureCentral and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.Toward biomarkers in multiple sclerosis: new advances.The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology.Noninvasive assessments of optic nerve neurodegeneration in transgenic mice with isolated optic neuritis.Phosphorylated neurofilament heavy chain is a marker of neurodegeneration in Leber hereditary optic neuropathy (LHON)Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.Protecting axons in multiple sclerosis.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.Review on intermediate filaments of the nervous system and their pathological alterations.Molecular biomarkers of neurodegeneration.Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis.Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis.Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.The relationship between subjective reports of fatigue and executive control in multiple sclerosisN-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.Cerebrospinal fluid ATP metabolites in multiple sclerosis.Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis.Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.The Validation Study of Neurofilament Heavy Chain and 8-hydroxy-2'-deoxyguanosine as Plasma Biomarkers of Clinical/Paraclinical Activity in First and Relapsing-Remitting Demyelination Acute Attacks.Amniotic fluid brain-specific proteins are biomarkers for spinal cord injury in experimental myelomeningocele.Degeneration of corpus callosum and recovery of motor function after stroke: a multimodal magnetic resonance imaging study.Science is 1% inspiration and 99% biomarkers.The Relationship Between Neurocognitive Behavior of Executive Functions and the EFPT in Individuals with Multiple Sclerosis.
P2860
Q21558407-13C2DDE0-D1D4-48F2-96AE-6253260B52D2Q26799233-DDA50EDC-C98D-43E6-B588-F28E7FE15529Q27496017-457F47FA-5009-47DB-8669-0FFEF4D5109CQ30712257-1ED8F007-26F6-49AC-97C2-2DCEEAAFEB8BQ33414966-60DD4B9D-EC39-4402-93BC-B367EE349D3FQ33657708-B1905666-EDCA-42F1-8851-576916C185A4Q34078026-9CBEECBA-6A14-4000-A3FA-D6660F040B43Q34924891-B02739FA-C543-4793-A36D-507F89126F06Q35078327-48220720-A2F2-487A-A21E-C067B3DABABAQ35878624-16AF328C-49FA-405A-A43A-97F979B0CCCDQ36327377-F5DB4377-4FC6-42D8-A5B0-7B6369ACB37BQ36492380-30C7C355-861B-4316-88C0-45BAAB1CB789Q36500261-CDC65050-3C6F-4473-A496-971198883B8AQ36973566-D0CACD73-5FA3-446B-83F4-8A4EFDCBBFBEQ36979239-A0C3903E-88EA-4367-AFDA-A59A1F529448Q37021025-3144C248-E6B8-470D-BC4B-8F27B35DB963Q37206262-C2F9F533-9946-4739-873C-0BA3EA6E2C03Q37218580-0BF36CC8-3F25-467F-847C-24382EDF0C24Q38088747-27D77744-C6C8-4338-B75E-2D18B1C45463Q38092972-0A11B52F-9C51-4B76-96DB-1986FF47D771Q38113164-EDD0D0EB-53E4-4EA6-989E-F8E7C7C566B6Q38154930-02397CB2-EC9D-4D71-8209-C3EA7D5D8149Q38713740-5020BF41-8E19-4A4B-BB5B-82B1AA622F3BQ38737766-96A7387D-542D-4454-9FB0-211C9CF85099Q38782456-1D169B95-4E8E-4AB0-B59D-2E7B2E1421BBQ39027028-8D3B34B3-BE70-4969-8058-57F881EB611BQ39748242-0FA84E1E-1001-4505-9C20-DDBA0A714088Q40997871-54ED10AB-378F-4583-8F37-0EF23D6EDFEFQ41909448-982E2756-564E-4C49-BF4A-54955B81685CQ42683530-E3547D0D-F164-41AE-94DA-F2379F6A0926Q43145621-B5DEB027-892A-4110-B95E-740056D08C36Q44028578-920C7059-6289-46D8-BB63-F260AAA79ACDQ46766236-DB293DDE-713D-437E-80CA-A8221C11A842Q47579410-DA4347E3-A086-4C54-90ED-56330BB3CDEBQ48482480-58EB4752-4D5B-486E-9A3C-48B5F041E27EQ48681179-53FB2F39-DFF5-4020-B7A6-BCD6BE99153BQ48763817-0C48AE81-9934-495A-AB52-AF6C795BCF08Q48824529-698D2512-AAC7-4001-BB7E-345329C8E41DQ50984144-5771AA14-DE2C-496A-B5AC-3898DD51E67CQ51522883-C4CF69E4-83A6-4807-A2AD-30A5942E9D40
P2860
Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Axonal damage accumulates in t ...... s: three year follow up study.
@ast
Axonal damage accumulates in t ...... s: three year follow up study.
@en
type
label
Axonal damage accumulates in t ...... s: three year follow up study.
@ast
Axonal damage accumulates in t ...... s: three year follow up study.
@en
prefLabel
Axonal damage accumulates in t ...... s: three year follow up study.
@ast
Axonal damage accumulates in t ...... s: three year follow up study.
@en
P2093
P2860
P356
P1476
Axonal damage accumulates in t ...... is: three year follow up study
@en
P2093
B M J Uitdehaag
C H Polman
E J Thompson
G Giovannoni
M J Eikelenboom
P2860
P304
P356
10.1136/JNNP.2004.043315
P407
P577
2005-02-01T00:00:00Z